Stephan Pilsinger: How a Practising GP Is Shaping Germany’s Prevention-First Health Reforms

Stephan Pilsinger presents recent austerity legislation as an essential correction that restores revenue-linked expenditure discipline within statutory health insurance reform while acknowledging isolated reimbursement reductions as counterproductive. His position centers on preserving broad benefit coverage through efficiency gains rather than across-the-board retrenchment. The interview underscores that clinical prevention measures, when integrated early, can avert downstream pharmaceutical and acute-care costs without diminishing the role of either generic or innovative medicines.

Restoring Discipline Through Statutory Health Insurance Reform

Pilsinger derives policy positions from his concurrent part-time general practice, which supplies direct observation of how legislative changes affect patient encounters, practice workflows, and inter-professional coordination. Committee responsibilities as pharmaceutical and hospital rapporteur further structure his analysis by requiring negotiation of specific reform packages such as the hospital and pharmacy laws. This dual vantage point allows translation of everyday care constraints into legislative priorities without reliance on abstract modeling alone. In the context of statutory health insurance reform, such grounded perspectives prove vital for balancing fiscal responsibility with patient access.

Evidence on Prevention and Market Access

Stephan Pilsinger discusses the elimination of the organ-donation counseling billing code, framing it as yielding negligible savings while risking lower registration rates because physician consultations represent a high-yield opportunity for informed discussion. Pharmacy contraction since 2013 is linked to cumulative pressures from manufacturer discounts, discount agreements, and elevated personnel and energy costs that push generic production offshore. In contrast, the Act on the Restructuring of the Pharmaceutical Market process is credited with delivering market entry within 47 to 54 days after European approval and a seven-month free-pricing window that continues to attract innovative products. These elements highlight how statutory health insurance reform can support both cost control and timely innovation when designed with clinical realities in mind.

Ad

Strategic Role of Outcomes Research

Health economics and outcomes research can quantify the long-term expenditure offsets from routine primary-care interventions such as blood-pressure, body-mass-index, and metabolic screening performed during existing visits. Market-access strategies should incorporate the revenue-based spending rule as a constraint that favors interventions demonstrating immediate or near-term budget neutrality. Reimbursement negotiations under the Act on the Restructuring of the Pharmaceutical Market framework remain central to maintaining early availability of high-cost therapies, suggesting that future adjustments will focus on preserving this timeline while addressing personalized-medicine pricing pressures. Stephan Pilsinger’s insights, drawn from his interview, emphasize integrating these approaches to sustain high-quality care amid ongoing statutory health insurance reform efforts.